Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced the completion of research alliance agreements that have been signed with TorreyPines Therapeutics, Inc. (Headquarters: California, USA, Acting CEO: Evelyn Graham) since 2002 for the discovery of genes associated with late onset Alzheimers disease (LOAD). Following the completion, the companies signed a new agreement in which Eisai will purchase all research data and assets obtained from such research activities conducted by TorreyPines Therapeutics.
The new agreement was based on the two consecutive research activities conducted by TorreyPines Therapeutics: the research focusing on the discovery of genes responsible for LOAD conducted from October 2002 to September 2005, and the genetic research program, focusing on unbiased genome-wide screening, to unveil the whole picture of the pathogenesis of the disease conducted from October 2005 to September 2008. With the new agreement, Eisai will purchase all research data and assets obtained from such research activities.
With these research data and assets, Eisai will continue to advance its research activities in order to create a next generation treatment for Alzheimers disease that is based on genetic information.
Eisai Co., Ltd.